MTOR and metabolic syndrome: Activation of GSK3 or JNK1 was not quantified in these subjects, but previously we reported that baseline phospho‐mTOR was not increased in metabolic syndrome subjects, although post resistance training the increase in mTOR activation was nearly twice that of the control subjects (Layne et al. 2011).